VALN•benzinga•
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026
Summary
Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga